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Summary Cardiac and pulmonary functions were evaluted in 75 patients aged 50 years or under, treated for
Hodgkin's disease by mantle radiotherapy at least 3 years earlier; all received the same mantle field
radiotherapy: radiotherapy alone, MOPP chemotherapy plus radiotherapy, MOPP and ABVD chemotherapy
plus radiotherapy.
No patient had any symptom of heart disease. Only borderline abnormalities of ECG or echocardiogram
were observed in 12 patients. One of them showed a moderate aortic stenosis which was known before the
treatment; apical or septum hypokinesia were present in four patients and one patient had a slightly right
ventricular dilatation.
Twelve (16%) chest radiographs showed moderate or severe abnormalities, but there was no significant
correlation between the results of pulmonary function tests and Xenon ventilation/perfusion scintigraphy, the
clinical examination and the intensity of the radiological sequelae. Twenty-nine (64%) Xenon scintigraphies
showed a reduction of lung perfusion in the irradiated areas without any symptom. The resting mean
pulmonary function test was significantly lower for the patients than for the control group with regard to
Total Capacity and Vital Capacity. The exercise tolerance, as indicated by analysis of blood gases, was below
the one expected for only two patients who were dyspneic during the low level ofexercise. We did not find any
significant difference between the three treatment groups.
We conclude that the treatment with mantle field under good technical conditions (high energy photons,
moderate doses ...) can result in minimal cardiopulmonary dysfunction.
Hodgkin's disease (HD) is a prototype for the successful
management of a previously incurable malignancy by the use
of an aggressive multimodal therapy. This results from
extended field megavoltage irradiation and/or combination of
chemotherapeutic agents which can be administered alter-
nately with radiation or sequencially. Since about 85-90% of
the patients in early stages of Hodgkin's disease can now be
cured (Kaplan, 1980; Tubiana et al., 1985), the problem of
late toxicity of the various treatment methods is now prevail-
ing. At least for limited stages, the role of the radiotherapist
is currently not only to cure the disease, but also to minimise
the risk of late complication.
Mantle field irradiation for the treatment of Hodgkin's
disease subject the heart and lungs to varying radiation doses
depending on the presence and extent of the intrathoracic
disease and on the radiation techniques used.
The literature contains a number of reports on both car-
diac and pulmonary complications, often severe, following
mantle field irradiation, but many of these reports concern
treatment techniques now considered as out of date (Apple-
feld et al., 1982; Do Pico et al., 1979; Gottdiener et al., 1983;
Host & Yale, 1973; Larson et al., 1976; Lokich et al., 1973).
More recent data suggest a dramatic decrease in these
sequelae over the past decade as a result of refined treatment
techniques (Carmel & Kaplan, 1976; Morgan et al., 1985;
Smith et al., 1989). However, sequelae are still too frequent
in the recent literature (Cosset et al., 1984; Cossett et al.,
1988; LaMonte et al., 1986; Pohjola-Sintonen et al., 1987;
Zarrabi et al., 1984; Zucali et al., 1981). Therefore, we have
evaluated the cardiopulmonary function at rest and during
exercise to study the effect of combined modality therapy on
cardiac and/or pulmonary function.
Our purpose was thus to evaluate the impact of the mantle
field irradiation techniques currently used, either alone or
combined with MOPP (DeVita et al., 1970) (nitrogen mus-
tard, vincristine, procarbazine, prednisone) with or without
ABVD (Bonadonna et al., 1975) (adriamycin, bleomycin,
vinblastine, dacarbazine), on long term cardiopulmonary
function.
Methods and patients
Patients
Between 1979 and 1986, 129 previously untreated patients
with HD, stages IA to IIIA, were irradiated at the 'Centre
Alexis Vautrin'. They were entered into a protocol utilising
MOPP/ABVD/Radiotherapy (RT). We selected 90 patients
(62 males and 28 females) who were disease-free survivors
between 18 and 50 years old at the time of the study; we
excluded patients treated by pediatric protocol treatment
(radiotherapy doses <20Gy) and the oldest patients who
could present with cardiopulmonary disease because of their
age; we asked them by mail to participate in the study. We
received 87 answers. Seventy-five (49 males and 26 females)
agreed to participate and came to hospital for 1 day. The
other patients refused to participate as they were living too
far away (five cases), because of lack of time (three cases), of
pregnancy (one case), of relapse being investigated in other
hospitals (two cases), or of intercurrent illness (one case).
The age at treatment ranged between 15 and 46 (average
29). The mean duration of follow-up was 5 years with a
minimum of 3 years and a maximum of 10 years. The age at
the time of the study ranged between 19 and 49 years
(average 34 years).
Treatments
The clinical and pathological stages are summarised in Table
I. We identified three treatment groups and one control
group:
(1) Group MOPP/RT: 19 patients, nine males and ten
females, treated with four or six courses of MOPP fol-
lowed by mantle irradiation.
(2) Group MOPP/ABVD/RT: 42 patients, 31 males and 11
females, alternately treated with two or three courses of
MOPP and ABVD followed by mantle irradiation. The
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Table I Clinical and pathological stages of patients in the different
treatment groups
Ann Arbor Group RT Group RT Group RTplus
stage Total alone plus MOPP MOPP/ABVD
IA 10 8 2 0
IB 0 0 0 0
IIA 29 6 7 16
IIB 23 0 5 18
IIIA 13 0 5 8
patients received two cycles of ABVD in 36 cases and
three cycles in six cases.
(3) Group RT alone: 14 patients, nine males and five
females. All of them had received mantle irradiation.
(4) Control group for the pulmonary function test: 24
patients, 12 males and 12 females without evidence of
disease. This group was formed by the Department of
Exercise Physiology; INSERM U 14, Dr Gimenez,
Vandoeuvre-les-Nancy, France.
The groups were similar in the constitution composition,
but the Group 2 had a significantly higher sex ratio than the
other groups.
Irradiation was applied to all patients in the same institu-
tion from a 25 MV photon beam from a linear accelerator
(Sagittaire CGR) with two opposed mantle fields as defined
by KAPLAN (Kaplan, 1980). The Cerrobend blocking tech-
nique was used to shield normal structures. Check films were
made at least once a week to check the block locating.
The dose, calculated in the midplane on the axis according
to the recommendation of ICRU (Report 29), was 36Gy
into 20 fractions in 56 cases and 39, 6 Gy into 22 fractions in
nine cases. This dose was given over 4 weeks, the two fields
being treated every day, 5 days a week. In vivo dose measure-
ments were made routinely during the first week of treat-
ment. The computerised dose distribution carried out for
each patient showed a good homogeneity.
No patient received any open-field whole lung irradiation
and a subcarinal block was added four times after 20 Gy.
In all cases, a 4 weeks' time span was observed between
the end of chemotherapy and the beginning of radiation
therapy.
Testing procedures
The patients were tested by physical examination, blood
count, chest radiographs, a standard 12 leads electrocardio-
gram (ECG), echocardiography (unfortunately, we could not
use radionuclide ejection fraction because of technical prob-
lems at the time of the study), pulmonary function test and
Xenon 133 ventilation/perfusion scintigraphy.
Chest radiographs. Pulmonaryfunction test. Xenon 133
ventilation/perfusion scintigraphy
Radiological grading of fibrosis and retraction were as follows:
Pulmonary dome retraction:
Grade 0: no change; Grade 1: ascent of the small fissure
of one and more intercostal space; Grade 2: hilar ascent;
Grade 3: ascent of the diaphragm.
Pulmonary dome and mediastinum fibrosis:
Grade 0: no change; Grade 1: slight; Grade 2: distinct;
Grade 3: severe.
The radiographs were interpreted twice by a radiologist.
The reproducibility of these criteria was 95%.
Pulmonary function tests (PFTS) were performed in 74
patients including the resting measurement of total lung
capacity (TLC) and all of its subdivisions, the various flow
rates resulting from forced expiratory flow curves, maximal
voluntary ventilation (MVV), time of equilibrium with
helium (He time), steady state diffusing capacity (DL 02)
(Lacoste et al., 1980). Arterial blood gases were obtained in
73 patients at rest. The results of the PFTS were expressed as
a percentage of the values predicted by the European Econo-
mic Community (Quanjer, 1983).
Forty-five Xenon 133 ventilation/perfusion scintigraphies
were performed with the technique described by LACOSTE
(Lacoste et al., 1980). In the other cases, it was impossible to
get '33Xe.
Assessment of the cardiac surface irradiated In order to
evaluate the role of the mediastinal volume irradiated, we
measured the cardiac surface on the simulator films by reduc-
ing it to simple geometrical figures. We take the inferior
border line of the aortical Button as a superior limit. So, we
assessed the percentage of the cardiac surface irradiated for
each patient. The reproducibility of these criteria was good
(90%).
Modified pulmonary function tests Pulmonary exercise test-
ing was performed in 64 patients on a ergometric bicycle. It
was not performed in 11 patients because of obesity (two
cases), technical problems (three cases), congenital paraplegy
(one case), lack of time (two cases), serious knee-disease (two
cases), refusal of the patient (one case). The time rate was
10 min with constant power, at the level of energy necessary
to obtain 80 to 90% of the Maximal Exercise Test (MET).
MET was determined with the maximal theoretical heart rate
given by the following formula: 220 - age of the patient
(Astrand, 1952; Astrad & Rodahl, 1970). The constant maxi-
mal power test was determined after the maximal supported
power (MSP) was measured for 20 mn (Gimenez et al., 1984).
Arterial blood gases were obtained before and at the end
of the exercise. The heart rate (HR) was checked continu-
ously. The blood pressure (BP) was determined by ausculta-
tion. HR and BP were obtained at rest, during every further
minute of exercise, immediately following the peak exercise
and during each minute of recovery until HR decreases to
100 beats per minute.
The analysis of blood gases was performed to determine
the modifications of P02, PCO2, pH and SaO2. The modifica-
tions of blood gases during maximal exercise is widely
accepted as one of the most objective measurement of the
physical fitness of individuals as reflected by their respiratory
and cardiovascular system. The major determinant of pH
and SaO2 during the maximal theoretical exercise MET are
the cardiac output and the oxidative capacity of the skeletal
muscle. Therefore, a fall in the pH and SaO2 during MET is
found in patients with decreasing cardiopulmonary function
(Gimenez et al., 1984).
Echocardiography An echocardiography was performed in
73 patients with 2-d and M-mode echocardiographic record-
ing. The ejection fraction was calculated according to the
Teicholtz's formula (Teicholtz et al., 1976).
For the analysis, we used a specific statistical data base
management system developed at the Institut Gustave Roussy
(Villejuif, France) (Wartelle et al., 1983). The Student's test
and Chi square test were used to compare the various treat-
ment groups for all parameters. A P value <0.05 was
accepted as statistically significant.
Results
Symptomatology
No patient presented with cardiac symptoms; only three
patients felt that they were more dyspneic during exercise
than before treatment, due to two of them to post surgical
phrenic paralysis and for the third one to an isolated restric-
tive syndrome.
Chest radiographs
The results of chest radiographs are summarised in Table II.
There was no significant correlation between the results of
pulmonary function test, clinical examination and the inten-
sity of the radiological sequelae. In two patients, the radio-910 C. ALLAVENA et al.
Table II Radiological sequelaeaccordingto thefollowing radiological
gradingoffibrosis andretraction: 1,Pulmonarydomeretraction: Grade
0, no change; Grade 1: ascent of the small fissure of one and more
intercostal space; Grade 2: hilar ascent; Grade 3: ascent of the
diaphragm. 2, Pulmonary dome and mediatinum fibrosis: Grade 0: no
change; Grade 1: slight; Grade 2: distinct; Grade 3: severe
Grade
0 1 2 3
Pulmonary dome retraction 44 29 2 0
Pulmonary dome fibrosis 43 20 12 1
Mediastinum fibrosis 58 14 3 0
graph showed phrenic paralysis appearing after surgical
thoracic exploration or a supra-clavicular node biopsy.
The percentage of the cardiac surface irradiated varies
from 49% to 90% with a mean values of 71.2%. We com-
pared these results to the different parameters studied and we
found only a significant correlation with the pH after exer-
cise. Indeed, the patients with over 75% of cardiac surface
irradiated have a pH significantly lower P = 0.05 (pH = 7.37,
s.d. = 0.02) than the other ones (pH = 7.31, s.d. = 0.02).
There is only a non-significative tendency for the SaO2 after
exercise P = 0.09 and the value of the total pulmonary
capacity P = 0.08.
Electrocardiography
No patient presented with ischemic signs on ECG. An abnor-
mality was found in six (9%) out of the 72 patients who
underwent an ECG examination. One had a partial right
bundle branch block, two a low voltage ECG (R < 15 mV in
limb leads), two a limit T wave change and one a limit ST
segment depression. Two had an borderline repolarisation
abnormality.
Echocardiography
Seventy-three 2-D and M mode echocardiography were com-
pleted. They showed an asymptomatic myxoid mitral degen-
eration in one patient, and a moderate aortic stenosis, in
another patient, that was known before treatment. The sep-
tum and the apex was borderline hypokinetic for two
patients each. One slightly dilatation of the right ventricle
was observed. There was not pericardial effusion. The ejec-
tion fraction calculated using the Teicholtz formula was nor-
mal and the mean was 60% (range from 51% to 75%). There
was no significant difference between the various treatment
groups.
Pulmonaryfunction tests
The mean of blood gases at rest were pH = 7.41 (s.d. = 0.04),
P02 = 96 (s.d. = 2.2), PCO2 = 39 (s.d. = 2.5), SaO2 = 95
(s.d. = 3.1). Only two patients had abnormal values. One had
phrenic paralysis and the other was very dyspneic during low
level of exercise.
The mean values of the treatment groups were within the
normal limits (20% of predicted normal value) for all para-
meters except for Vital Capacity (VC) and Total Capacity
(TC). The treatment groups, which included mantle irradia-
tion, showed mean VC and TC that were lower than the
control values (Table III). Eleven patients had moderate
restrictive lung disease (three in group 1, four in group 2 and
four in group 3). One with phrenic paralysis had severe
restrictive and obstructive disease.
Only five patients had a borderline decrease in diffusion
capacity (two in group 1 and two in group 2).
There were no significant differences between the treatment
procedures in acutal performance for any of the pulmonary
function parameters.
Xenon scintigraphy
The Xenon scintigraphies showed, in 29 cases (64%), a
reduction of the lung perfusion in the irradiated areas. The
ventilation was not modified. There was no correlation
between the results of Xenon scintigraphy, of pulmonary
function test, of chest radiograph and of clinical examina-
tion.
Pulmonary exercise test
Three patients had to stop the test on a low exercise level
(two women< 100 W during 4 min and one man< 150 W at
6 mn) because offatigue. However, on the whole, the exercise
was perfectly tolerated.
Neither rythm disturbances, nor chest pain were observed.
Eight patients had tachycardia (HR>100) already at rest
probably because they were anxious. No patient was tachy-
cardic after the end of the interview.
The results of the pulmonary exercise test are summarised
in Table IV. There was no sigificant difference with the
reference population and between the different treatment
groups.
Only one patient, who was dyspneic during exercise, had a
significant decrease in SaO2 but not ofpH. The other patient,
who was very dyspneic because of phrenic paralysis, refused
the exercise test. One patient with phrenic paralysis, but who
had a sport activity, had normal of pH and SaO2 values
during effort.
Discussion
The incidence of electrocardiographic abnormalities in
patients who recieve mantle irradiation is low compared to
other reports. Generally, a 25% incidence of findings includ-
ing ST segment depression, T wave changes, minor QRS
abnormalities and occasional silent myocardial infarction are
reported (Brosius et al., 1981; LaMonte et al., 1986; Larson
et al., 1976; McReynolds et al., 1976; Pohjola-Sintonen et al.,
1987; Watchie et al., 1987; Zarrabi et al., 1984). Watchie et
al. (1987) found a 13% incidence of complete or incomplete
right bundle branch blocks. We report only seven (9%)
abnormal ECG. Six had minor abnormalities.
The incidence (5%) of pericardial effusion is low in this
series. Pohjola et al. (1987) reported an incidence of 38% of
pericardial effusion more than 5 years after mediastinal irrad-
iation. Gottdiener et al. (1983) gave 36%. However a pericar-
Table III Mean±standard deviation of the pulmonary function tests in the different
treatment groups and in the control group.
Pulmonaryfunction test
Groups VC% TC% DuO2 VEMS/CV Tested
Control 114±2.5 107± 1.1 109±2.2 78.6± 1.1 24
Studies (all) 97.7± 14 92.7± 12 112±22 81.5±4.2 7
P <0.05 <0.05 NS NS
RT + MOPP 99± 12 96±12 112±23 82±8.5 18
RT+ABVD/MOPP 97±15 92±12 111±23 80.8±6 42
RT alone 98±12 95±11 111±23 81±8 14
P NS NS NS NS
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Table IV Mean± standard deviation of the exercise tests
SaO2 Arterial PCO2 Stop
decrease bloodpH after arterial blood exercise before
Mean age Number % MET after exercise exercise after exercise 10 mn
Treated group 25±6 64 86±5 1±2.09 7.35±0.04 32±5 3
MOPP + RT group 25±5 13 85±5 0.83± 1.1 7.32±0.05 31±3 1
MOPP + ABVD + RT group 24±6 39 86±5 1.2±2.5 7.35±0.04 32±5 2
RT alone group 28±6 12 83±4 0.7±0.9 7.34±0.04 33±3 0
Control group 28±7 24 88±2 0.9±2.0 7.35±0.04 32±4 0
P NS <0.05 NS NS NS NS NS
NS = not significant.
ditis rate as low as 13% was reported by Carmel and Kaplan
(1976).
Two patients of our series had a history of pericarditis 6
months after treatment. One of them presented with pericar-
dial effusion which completely regressed in 3 months with
medical treatment; the second one presented with a huge
pericardial effusion treated by surgical drainage; both were
asymptomatic respectively 36 and 45 months later. At the
time of the echocardiography, it was not possible to report
any pericardial effusion.
Nevertheless, we are describing only clinical pericardial
effusions since we did not check them carefully during treat-
ment in all patients by echocardiography. Had we used this
procedure, the incidence of abnormalities would probably be
higher. In our study, the echocardiography was performed, at
the time of the study, 3 years or more after the end of
treatment. Morgan et al. (1985) who performed echocardio-
graphy more than 5 years after the end of treatment found
8% of minor pericardial effusion. However, we attribute this
lower incidence to the use of equally weighed fields treated
every day by high energy Linac and to the use of a limited
dose of 36 Gy in the mediastinum in patients in complete
remission with no enlarged mediastinal nodes.
Burns et al. (1983) found a 57% incidence of abnormal
ventricular function, but those patients had recieved doses of
irradiation of up to 76 Gy which excess the therapeutic
range. A similar incidence of abnormalities of ventricular
function was reported by Gottdiener et al. (1983). Never-
theless, this group had been treated with a single antero-
posterior field, a technique that is not commonly used. Both
last studies included older patients who have an increased
likelihood ofconcomitant coronary artery disease and neither
study evaluated other possible causes of ventricular dysfunc-
tion. Morgan et al. (1985) for patients under 35 years found
25% of ventricular abnormalities with sensitive radionuclide
ventriculography.
We found abnormal ventricular function only in 6%. This
incidence of cardiac abnormality is less than previously
reported and partially reflects the selection of patients for
study, but probably the low sensitivity of the echocardio-
graphy too. However, we can be sure that our patients do
not present with serious cardiac sequelae.
The linear accelerator of 25 MV used, gives a lower dose
to the heart than 'Co or 8 MV LinAc as described in other
studies (Brosius et al., 1981; Carmel & Kaplan, 1976; Cosset
et al., 1984; La Monte et al., 1986; Larson et al., 1976;
McReynolds et al., 1976; Pohjola-Sintonen et al., 1987;
Watchie et al., 1987; Zarrabi et al., 1984); 1.8 Gy to a
maximum of 2 Gy per fraction, five fractions per week, the
two fields being treated every day, all these precautions are
probably important to reduce late sequelae. Nevertheless, our
follow-up is still too short to conclude.
The cardiovascular sequelae were too low to be compared
between the different treatment groups. Santoro et al. (1982;
1987) and Cosset et al. (1989) showed that pulmonary tox-
icity was more important with ABVD. However, in our
series, it was not possible to confirm these results as the
follow-up was still too short.
Previous studies evaluating the effects of mantle irradiation
on pulmonary function found a significant decrease in Total
Lung Capacity, Vital Capacity, Inspiratory Capacity, and
Diffusion Capacity associated with radiological infiltrative
signs, 2 to 6 months after completion of the treatment. They
disagree as to whether these modifications lessen over 1 to 2
years following the treatment (Lokich et al., 1973).
Several researchers have examined the short-term effects of
mantle irradition on lung function. Findings include acute
but transient decreases in PFTs over the first 6 months with
return to pretreatment values by 8-12 months (DoPico et al.,
1979; Evans et al., 1974; Smith et al., 1989). Nevertheless
Zuccali et al. (1981), or Pohjola (1987) reported a significant
decrease in vital capacity and inspiratory capacity in 30% of
the patients, sometimes severe, more than 12 months after
treatment. The follow-up of the patients in our series lasted
more than 2 years and can explain our low sequelae level.
Host et al. (1973) and Larson et al. (1976) evaluated the
effects of mantle irradiation and found a mild restrictive
ventilatory impairment marked by a decrease in lung volume
at 9-23 months. Smith et al. (1989) confirmed acute changes
in lung volumes and spirometry after mantle irradiation,
which resolve within 2 years and are not of sufficient degree
to cause symptomatology or to extend outside the range of
normal.
There is much less information available on the late effects
of mantle irradiation on pulmonary function. Morgan et al.
(1985) and Smith et al. (1989) found only minor reduction in
lung volume and moderate decrease in DL CO at more than
4 years of follow-up.
Watchie et al. (1987) or Tarbell et al. (1990) showed that
the use of either chemotherapy followed by radiotherapy
might minimise functional changes. In our study, the size of
the mediastinal volume, evaluated by the position of the
cardiac surface irradiated allows to state that over 75% the
tolerance to exercise measured by the diminution of the
blood pH and of the SaO2 is less good; and there is a
tendency to a diminution of the pulmonary volume. It seems
that the importance of the mediastinal volume irradiated
affects the cardiorespiratory function after the treatment. It is
probably difficult to evidence it in this method since the
variations are light as the incidence of the sequelae. The
comparison with the Watchie's study that involved extensive
radiotherapy is difficult.
We did not find a significant decrease in exercise perfor-
mance. Two patients were dyspneic during low level of exer-
cise, but one had phrenic paralysis. The second patient who
also had a phrenic paralysis, had an excellent reeducation
and his functional exercise test was in the normal limits.
Our study indicates that mantle field radiotherapy for
Hodgkin's disease produces few functionally significant
sequelae at long term follow-up despite the reduction of the
lung perfusion in the irradiated areas showed by Xenon
scintigraphy. It seems, with our study, that any technique
improvements such as attention to the fractionation schedule,
in vivo dosimetry, high energy Linac, reduction of the media-
tinal volume irradiated by chemotherapy etc...., may reduce
the incidence of cardiopulmonary abnormalities. Therefore,
the therapeutic trials for Hodgkin's disease must not only
address the question ofsurvival and cure but the reduction of
late effects in those 80-90% of the patients that will be long
term survivors.912 C. ALLAVENA et al.
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